Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) [Phase 1]

View source ↗

Summary

Phase 1 trial in Japanese participants assessing safety, tolerability, and pharmacokinetics of idelalisib in relapsed or refractory indolent B-cell non-Hodgkin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Lymphoplasmacytic Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2021-03-19